Navigation Links
Savient Provides Update on Pegloticase BLA
Date:2/12/2009

  • Revised Prescribing Information. Upon further review, the Committee has determined that although both the every 4 week dose regimen and every 2 week dose regimen have met the primary endpoints demonstrating that the drug works as compared to the effects of placebo, the every 2 week dose regimen presents a much clearer path toward FDA approval due to the significant medically and clinically relevant benefit demonstrated as early as week 13 in the randomized clinical trials. Thus, the Company has determined to focus exclusively on the every 2 week dose regimen and will recommend this dosage for approval. Patients in the every 2 week dose regimen have demonstrated statistically significant clinical improvements including the reduction and resolution of gout tophi. Other statistically and clinically meaningful improvements included decreases in tender or swollen joint counts, reduction in flare incidences and frequency in months 4 to 6 of treatment, and meaningful improvements in pain reduction and health related quality of life measures at 6 months compared to placebo.

"I believe the recent amendments significantly enhance the overall application and better position the BLA to undergo a satisfactory FDA review. This is an exciting new therapy that, if approved, has the potential to have a meaningful impact on the patients who need it," said Dr. Simon. "Through our multi-faceted review, which included new analyses and further interpretation of data from a number of external experts, we have gained a greater understanding of the relative safety and efficacy of pegloticase and further clarification on the most appropriate uses for this product. Significantly, the data also confirms that a death imbalance of pegloticase does not exist."

Improved Understanding of the Cardiovascular Profile

In late November 2008, the Company enga
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
2. USAID Provides Malaria Assistance to Zimbabwe
3. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. American Dairy Provides Business Update
6. Alfacell Provides ONCONASE(R) NDA Submission Update
7. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
8. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
9. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... -- Sleep Specialists, LLC a medical device company ... Solutions, a leader in digital health and chronic ... and cost reduction program for patients with Obstructive ... chronic medical condition characterized by periods of interrupted ... risk for cardiovascular disease, hypertension, stroke, congestive heart ...
(Date:9/1/2015)... 1, 2015 Taiwan,s ... conference in Taipei on  August ... Vaucarrin™ platform, a targeted drug delivery technology that uses ... This event was part of a joint press conference held ... Inc. (GNT), showcasing GNT,s latest edible gold-based food and ...
(Date:9/1/2015)... 1, 2015 The global ... basis of sectors, products & services and application. And ... with the increasing demand of advanced drugs for ... propel the growth for bioinformatics market. The implementation ... is known as bioinformatics. Decreasing cost of DNA ...
Breaking Medicine Technology:Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 2GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 3GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 4GNTbm Updates Developments in the Vaucarrin(TM) annogold Drug Delivery Platform 5Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 2Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 3Global Bioinformatics Market Valued at Over $1.3 Billion in 2013 and is Expected to Grow at CAGR of 20.3% From 2014 to 2020: Hexa Research 4
... 2012 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today ... The net loss for the first quarter ended ... of $16.0 million during the same period in 2011. The net ... one-time expense of $2.8 million for the purchase of a data ...
... 3, 2012  Gen-Probe Incorporated (NASDAQ: GPRO ) announced ... upcoming investor conferences previously announced on April 26, 2012, and ... conferences: , Deutsche Bank 37th Annual Health Care ... Time;  , Baird,s 2012 Growth Stock Conference in Chicago ...
Cached Medicine Technology:MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results 5Gen-Probe Withdraws from Previously Announced Investor Presentations 2
(Date:9/1/2015)... ... 01, 2015 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) ... the LATINA Style 50 Report that recognizes companies that provide the best career opportunities ... BCBSNJ climbs from number 24 to 21 of the 50 Best Companies for Latinas. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly ... Society for Dermatologic Surgery, according to a new survey that also offers insight ... Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical treatments and ratings ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... that creates negative pressure inside a wound to remove exudates, fluid, and infectious ... devices (comprising portable devices, stand-alone devices, disposable devices, and canisters, etc.) is projected ...
(Date:9/1/2015)... NJ (PRWEB) , ... September 01, 2015 , ... ... with Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, ... for cancer patients. , Editorial and marketing groups within OncLive, which provides ...
(Date:9/1/2015)... ... 01, 2015 , ... PetPace, the provider of an innovative ... activity, today announced its integration with leading veterinary Practice Management Software vendor Cornerstone. ... Practice Management Software packages in the US. Practice Management Software helps veterinarians manage ...
Breaking Medicine News(10 mins):Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 2Health News:Horizon Blue Cross Blue Shield of New Jersey Named One of the 50 Best Companies for Latinas by Latina Style Magazine 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2
... , , , , ... Jan. 28 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (OTC ... manufacturer and supplier of pharmaceutical,products and medical nutrients addressing ... January 22, 2010 , its Board of Directors ...
... ... it has been selected by Central Garden & Pet Company (NASDAQ:CENT) as its sole ... ... the leading MSDS and chemical data management company, announced today that it has been ...
... ... data is much easier these days for Abba House – a 12-month ... Since partnering with Global Vision Technologies (GVT) and implementing FAMCare® – ... their data faster – giving them a clearer picture of how their ...
... ... against a disabled person. , ... San Jose, CA (PRWEB) January 28, 2010 -- Covidien, formerly Tyco Healthcare, with revenue in ... discriminated against and refused to hire a potential employee based solely on the fact that ...
... Vibrant ... arthritis pain relief blog. Painreliefcream.info provides news, updates and information on arthritis and joint ... ... the sponsorship of http://www.painreliefcream.info/ a specialty arthritis pain relief blog. Painreliefcream.info provides ...
... ... international events for Valentine,s weekend in Las Vegas: The USA ... the Power Pilates "Power Higher" Conference will host Pilates professionals worldwide. ... teams, Pilates professionals and thousands of spectators from around the world ...
Cached Medicine News:Health News:Biostar Pharmaceuticals, Inc. Announces Change of Auditor 2Health News:Biostar Pharmaceuticals, Inc. Announces Change of Auditor 3Health News:Central Garden & Pet Selects SiteHawk as Its MSDS Management Provider 2Health News:Abba House Partners With Global Vision Technologies - First Adult Residential Case Management System of Its Kind 2Health News:Abba House Partners With Global Vision Technologies - First Adult Residential Case Management System of Its Kind 3Health News:Abba House Partners With Global Vision Technologies - First Adult Residential Case Management System of Its Kind 4Health News:Covidien Sued By Samuelson, Wilson and Roe for Disability Discrimination 2Health News:Covidien Sued By Samuelson, Wilson and Roe for Disability Discrimination 3Health News:Vibrant Health Co Sponsors Specialty Arthritis Pain Relief Blog, painreliefcream.info 2Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 2Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 3Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 4Health News:Rugby & Pilates Have a Date for Valentine's Weekend in Vegas 5
... volume Finnpipette Techpette combines form ... performance pipette. Advanced pipetting technology, ... ensures quality, safety, comfort and ... volume range is an important ...
Inquire...
... ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No cleaning, ... 100-1000 Inaccuracy (%) ... Imprecision(%) ... 10 Dimensions: ...
... Finnpipette Focus from Thermo Labsystems was designed ... Advanced features such as the new ... adjustment on microvolumes help to define this ... pipettes. The new interchangeable handle plate offers ...
Medicine Products: